Ranbaxy and GSK Enter R&D Agreement

Ranbaxy Laboratories (Gurgaon), India’s biggest pharmaceuticals company, has signed a multiyear R&D agreement with GlaxoSmithKline (GSK). Ranbaxy could receive more than $100 million in milestone payments for a product it develops and is subsequently launched by GSK, in multiple indications and up to double-digit royalties on worldwide net sales, under the terms of the agreement. “GSK will be able to develop more products faster by collaborating with our R&D team, and Ranbaxy will benefit from GSK’s vast drug discovery and development...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers